“LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING” (2021) Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021065. doi:10.4084/MJHID.2021.065.